APP Pharmaceuticals releases preservative-free Methotrexate; Ranbaxy selling generic Lipitor in Europe;

> APP Pharmaceuticals ($APPX), which two weeks ago received FDA approval to make preservative-free Methotrexate at its manufacturing facility in Melrose Park, IL, has released 35,000 vials of Methotrexate Injection, USP, and 10,000 vials of preservative-free Methotrexate Injection, USP, which should soon be available to clinicians to ease shortage issues. Story

> Per its agreement with Pfizer ($PFE), Ranbaxy Laboratories ($RANBXY.NS) is selling a generic version of Lipitor in Germany, Italy, Sweden and the Netherlands. Story

> Endo Pharmaceuticals Holdings ($ENDP), maker of the Opana ER painkiller, will ask shareholders to approve a name change to Endo Health Solutions Inc. Release

> Merck KGaA ($MRK.DE) has donated to the Zambian Health Ministry 5 mobile labs to be used to detect counterfeit medications. Release  

> Ann Arbor, MI.-based Rubicon Genomics, has selected Velesco Pharmaceutical Services, which has a 10,000 square foot manufacturing facility in nearby Kalamazoo, MI, to manufacture breast cancer diagnostics kits Rubicon is providing to Agendia, a molecular diagnostics company. Release  

> Chemist Cheng Yi Liang, who worked for the FDA's Center for Drug Evaluation and Research, was sentenced to 5 years in prison for trading on insider information to make $3.78 million. Story

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.